Omnio Healer selects Eden Biodesign for production of wound healing and anti-infection products
20 August 2009
Swedish company Omnio Healer AB has selected Eden Biodesign to provide process development and production services for Omnio Healer’s wound healing and anti-infection products for supplying the products for clinical trials.
Based on a novel therapeutic concept for wound healing and anti-infection, Omnio Healer is developing drug candidates with potent pro-inflammatory functions. The agreement with Eden Biodesign relates to the expression of proteins through mammalian cell culture for use against several clinical indications primarily focused on chronic eardrum wound studies.
Eden Biodesign was selected as Omnio Healer’s preferred manufacturing partner after an extensive due diligence exercise that evaluated numerous contract manufacturing organizations in both Europe and the United States.
Eden Biodesign will undertake the development of a robust manufacturing process that will lead to cGMP (current good manufacturing practice) production for supplying clinical studies. Omnio Healer has also assessed Eden Biodesign as a potential future commercial manufacturer of resulting product through the use of Eden’s MHRA-inspected state-of-the-art cGMP manufacturing facilities located in Liverpool, UK.
“We are extremely happy to have been selected by Omnio Healer to support the development of this important product. Based on our extensive experience, industry expertise, and first-class facilities, we hope to be able to add considerable value and flexibility to Omnio Healer’s development program,” said Eden Biodesign’s CEO, Dr. Crawford Brown.
“Our protein product has shown very promising preclinical results in wound healing indications. We are now very keen to take the next step and gain access to GMP-material for use in clinical trials. At the same time, we have every confidence that Eden Biodesign will become a valuable partner in this regard, as they can provide both cGMP process development and production,” said Mats Strömqvist, CEO of Omnio Healer AB.
Bookmark this page